Allergy and Placebo – Psychobiological predictors of the outcome after allergy treatment (the AllP study) – a pilot study

Allergy and Placebo – Psychobiological predictors of the outcome after allergy treatment (the AllP study) – a pilot study - AllP

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027338

Enrollment

191

Registered

2021-12-01

Start date

2022-08-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J30.1 J30.2 J30.3 J30.4 J45

Interventions

Group 1: The planned study is a prospective observational study encompassing several assessment time points. Patients routinely are seen every 3 months for a maximum of 36 months in the allergic consu

Mask-Air) regarding several psychological constructs (i.e., the subjective illness-related disability). At every assessment, blood samples will be collected to assess inflammatory and immunological pa

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients with an indication for allergic medical treatment (anti-allergic medication or allergen immunotherapy) due to allergic rhinitis - age > 18 - sufficient knowledge of the German language - ability to give informed consent

Exclusion criteria

Exclusion criteria: - No indication for medical treatment of allergic rhinitis

Design outcomes

Primary

Measure	Time frame
Subjective disability due to allergic symptoms (visual analog scale (VAS)) (www.mask-air.com) 12 months after the start of the medical treatment. This outcome will be assessed via an electronic diary (smartphone app).	—

Secondary

Measure	Time frame
- subjective quality of life (RQLQ/S) - treatment expectations and previous treatment experiences (Generic Rating for Treatment pre-Experiences, Treatment Expectations, and Treatment Effects, G-EEE) - illness beliefs: expected personal control, expected treatment control, expected consequences of the illness (IPQ-E) - illness-related disability (PDI) - ARIA (Allergic Rhinitis and its Impact on Asthma)-criteria - Sinunasal symptoms (SNOT-22) - Asthma control test (ACT) - Optimism (LOT-R) - Depression (PHQ-9) - Anxiety (GAD-7) - Beliefs about medicine (BMQ) - Social support (ESSI) - Health status and medical variables - Soziodemographic factors (i.e., age, sex, education) - immune and inflammatory paramters - medical treatment (anti-allergic medication, allergen immunotherapy)	—

Measure

Time frame

- subjective quality of life (RQLQ/S) - treatment expectations and previous treatment experiences (Generic Rating for Treatment pre-Experiences, Treatment Expectations, and Treatment Effects, G-EEE) - illness beliefs: expected personal control, expected treatment control, expected consequences of the illness (IPQ-E) - illness-related disability (PDI) - ARIA (Allergic Rhinitis and its Impact on Asthma)-criteria - Sinunasal symptoms (SNOT-22) - Asthma control test (ACT) - Optimism (LOT-R) - Depression (PHQ-9) - Anxiety (GAD-7) - Beliefs about medicine (BMQ) - Social support (ESSI) - Health status and medical variables - Soziodemographic factors (i.e., age, sex, education) - immune and inflammatory paramters - medical treatment (anti-allergic medication, allergen immunotherapy)

—

Countries

Germany

Contacts

Public ContactOliver Pfaar

Sektion Rhinologie und AllergologieHals-, Nasen- und OhrenklinikUKGM Marburg

oliver@pfaar.org06421-5866933

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026